This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Osteoporosis	Sialic acid binding Ig-like lectin 15 (SIGLEC15)	Cell-based and mouse studies suggest inhibition of SIGLEC15 could help prevent osteoclast-mediated bone destruction in osteoporosis and other bone-loss disorders. <i>In vitro</i> , an anti-SIGLEC15 mAb decreased formation of osteoclasts from precursor cells compared with control antibody. In young mice, the anti-SIGLEC15 mAb increased bone mineral density and trabecular bone volume and decreased serum osteoclast marker activity compared with control antibody. Next steps include testing SIGLEC15 inhibitors in models of cancer-induced bone loss.	Patented by Alethia BioTherapeutics Inc.; unavailable for licensing	Stuible, M. <i>et al. J. Biol. Chem.</i> ; published online Jan. 20, 2014; doi:10.1074/jbc.M113.494542 Contact: Gilles B. Tremblay, Alethia BioTherapeutics Inc., Montreal, Quebec, Canada e-mail: gilles.tremblay@alethiabio.com
<i>SciBX</i> 7(10); doi:10.1038/scibx.2014.288 Published online March 13, 2014				